Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen

Bone Marrow Transplantation

Volumn 50, Issue 1, 2015, Pages 113-120

  Ikezoe, T ^a   Yang, J ^a   Nishioka, C ^a   Yokoyama, A ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN DEGRADATION PRODUCT; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; RECOMBINANT THROMBOMODULIN; THROMBOMODULIN; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING DISORDER; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL RATE; TREATMENT DURATION; ALLOGRAFT; ANIMAL; GRAFT VS HOST DISEASE; HUMAN; IMMUNOLOGY; PATHOLOGY;

ALLOGRAFTS; ANIMALS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES, REGULATORY; THROMBOMODULIN;

EID: 84920658237     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.208     Document Type: Article

References (27)

1. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 718-721.
2. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, doubleblind clinical trial. J Thromb Haemost 2007; 5: 31-41.
3. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol 2014; 100: 27-37.
4. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
5. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-577.
6. Ikezoe T, Yang J, Nishioka C, Honda G, Furihata M, Yokoyama A. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol 2012; 32: 2259-2270.
7. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-785.
8. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 803-805.
9. Ikezoe T, Takeuchi A, Taniguchi A, Togitani K, Yokoyama A. Recombinant human soluble thrombomodulin counteracts capillary leakage associated with engraftment syndrome. Bone Marrow Transplant 2011; 46: 616-618.
10. Ikezoe T, Takeuchi A, Chi S, Takaoka M, Anabuki K, Kim T et al. Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation. Eur J Haematol 2013; 91: 442-447.
11. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685-1692.
12. Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. Haematologica 2014; 99: 541-547.
13. Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013; 19: 22-27.
14. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37: 2181-2186.
15. Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W et al. Non-obese diabetic-recombination activating gene-1 (NODRag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 2008; 154: 270-284.
16. Ikezoe T, Yang Y, Heber D, Taguchi H, Koeffler HP. PC-SPES: a potent inhibitor of nuclear factor-kappa B rescues mice from lipopolysaccharide-induced septic shock. Mol Pharmacol 2003; 64: 1521-1529.
17. Gallez-Hawkins GM, Thao L, Palmer J, Dagis A, Li X, Franck AE et al. Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 872-880.
18. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
19. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185-192.
20. Nomura S, Ozasa R, Nakanishi T, Fujita S, Miyaji M, Mori S et al. Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation?. Thromb Haemost 2011; 105: 1118-1120.
21. Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813-1824.
22. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013; 39: 644-652.
23. Kudo D, Toyama M, Aoyagi T, Akahori Y, Yamamoto H, Ishii K et al. Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin Exp Immunol 2013; 173: 276-287.
24. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-2181.
25. Gando S, Kameue T, Matsuda N, Hayakawa M, Hoshino H, Kato H. Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation. Thromb Res 2005; 116: 91-100.
26. Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46: 1495-1502.
27. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med 2012; 18: 1123-1129.